Armata enters ATM offering agreement for up to $100M of common stock

Armata Pharmaceuticals, Inc.

• Entered Capital on Demand Sales Agreement with JonesTrading for at-the-market offering of common stock up to $100M.
• JonesTrading will earn commission of up to 3.0% of gross proceeds; sales may be made on NYSE American.
• Company not obligated to sell; Jones not obligated to buy; program entirely at Company's discretion.
• Offered under existing S-3 registration statement (File No. 333-289585) and prospectus supplement dated Dec 1, 2025.
• Agreement contains customary representations, warranties, and indemnification; either party may terminate on three days' notice.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.